BBIO vs IONS
BridgeBio Pharma, Inc. and Ionis Pharmaceuticals, Inc., both Healthcare
BridgeBio Pharma, Inc. is the larger company at $13B against $12B. Over the past year BBIO returned +73% against +54% for IONS. Ryufin's sector-relative Smart Score puts IONS ahead, 9/10 against 3/10.
| Figure | BBIO | IONS |
|---|---|---|
| Last close | $79.36 | $63.37 |
| Market cap | $13B | $12B |
| 1-year return | +73% | +54% |
| 5-year return | +52% | +68% |
| Ryufin Smart Scoresector-relative, 1–10 | 3/10 | 9/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
BridgeBio Pharma, Inc.
Revenue of $244M in Q2 2026, net income null. Its largest reported line is License Services And Royalty, 45% of the disclosed total.
Ionis Pharmaceuticals, Inc.
Revenue of $268M in Q2 2026, net income null. Its largest reported line is Royalty, 28% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.